Table 3 Potential drugs for schizophrenia treatment
From: A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case
Potential SCZ drug | Indicationa | ATC codes | Number of SCZ clinical trials |
|---|---|---|---|
Citalopram | Depression | N06AB04; N06AB10 | 13 |
Atomoxetine | ADHDb | N06BA09 | 8 |
Memantine | Parkinson's disease | N06DX01 | 6 |
Paroxetine | Depression | N06AB05 | 6 |
Sertraline | Depression | N06AB06 | 5 |
Fluvoxamine | Depression | N06AB08 | 4 |
Lorazepam | Anxiety | N05BA06 | 4 |
Ondansetron | Nausea and vomiting | A04AA01 | 4 |
Dexmethylphenidate | ADHD | N06BA11 | 3 |
Fluoxetine | Depression | N06AB03 | 3 |
Methylphenidate | ADHD | N06BA04 | 3 |
Benztropine | Parkinson's disease | Â | 2 |
Betahistine | Obesity | N07CA01 | 2 |
Clonidine | ADHD | C02AC01; N02CX02; S01EA04; S01EA03 | 2 |
Famotidine | Peptic ulcer disease | A02BA03 | 2 |
Guanfacine | Hypertension | C02AC02 | 2 |
Mirtazapine | Depression | N06AX11 | 2 |
Pergolide | Parkinson's disease | N04BC02 | 2 |
Reboxetine | Depression | N06AX18 | 2 |
Zolpidem | Insomnia | N05CF02 | 2 |
Agomelatine | Depression | N06AX22 | 1 |
Bromocriptine | Parkinson's disease | G02CB01; N04BC01 | 1 |
Buspirone | Anxiety | N05BE01 | 1 |
Cinnarizine | Nausea and vomiting | N07CA02 | 1 |
Cyproheptadine | Allergies | R06AX02 | 1 |
Desipramine | Depression | N06AA01 | 1 |
Dexmedetomidine | Anxiety | N05CM18 | 1 |
Diazepam | Anxiety | N05BA01; N05BA17 | 1 |
Dopamine | Parkinson's disease | C01CA04 | 1 |
Levodopa | Parkinson's disease | N04BA01; N04BA04 | 1 |
Methamphetamine | ADHD | N06BA03 | 1 |
Naratriptan | Migraine headaches | N02CC02 | 1 |
Nitrazepam | Insomnia | N05CD02 | 1 |
Nizatidine | Peptic ulcer disease | A02BA04 | 1 |
Pramipexole | Parkinson's disease | N04BC05 | 1 |
Promethazine | Allergies | D04AA10; R06AD02; R06AD05 | 1 |
Sibutramine | Obesity | A08AA10 | 1 |
Trazodone | Depression | N06AX05 | 1 |
Zotepine | Â | N05AX11 | 1 |
Total | Â | Â | 82 |